Equities Analysts Offer Predictions for CYCC FY2024 Earnings

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Research analysts at Roth Capital boosted their FY2024 earnings estimates for Cyclacel Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff now forecasts that the biotechnology company will earn ($1.95) per share for the year, up from their previous forecast of ($2.29). Roth Capital currently has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q4 2024 earnings at ($0.29) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at $3.67 EPS and FY2028 earnings at $5.49 EPS.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million.

Separately, StockNews.com assumed coverage on Cyclacel Pharmaceuticals in a research note on Friday. They issued a “sell” rating on the stock.

Cyclacel Pharmaceuticals Price Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.37 on Friday. The firm has a market cap of $804,474.00, a price-to-earnings ratio of -0.04 and a beta of 0.56. Cyclacel Pharmaceuticals has a one year low of $0.35 and a one year high of $6.00. The stock’s 50-day moving average is $0.85 and its 200-day moving average is $1.42.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 23.58% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.